Déclarations de confidentialité

Caroline Thielen, (PhD)

SRIW REPRESENTATIVE

Caroline THIELEN is Investment Manager – Life Sciences at S.R.I.W. and Board Member of several biotech and medtech companies. Over the past 20 years, Caroline has gained solid experience in coordinating research projects at national and international levels. Prior to being appointed to her current position, she has served as COO of B2H, a major player in the development and reinforcement of the healthcare sector in connection with the academic research at ULiège and CHU de Liège. Caroline holds a Master’s degree in Biology and a PhD in Immunology from the ULiège completed by a postdoctoral training at the CDC.

Jean-Michel FOIDART (MD, PhD)

MEMBER OF THE BOARD

J.M. Foidart is an MD, PhD trained in Ob-Gyn, at the Johns Hopkins Hospital, Baltimore -USA, and in Belgium, Finland and France. He spent 3 years at the National Institutes of Health, in Bethesda, USA. He became in 1988, chairman of the Dept of Cell Biology and in 1996 of the Dept of Ob-Gyn at the University of Liege, Belgium. Dr. Honoris Causae at la Sorbonne-Pierre et Marie Curie, (Paris 2010) and Paul Sabatier University (Toulouse 2012), He co-created in 1999, Mithra a company now on the stock market. His publications were cited more than 49.000 times with a H index of 115. He is a member of the French and Belgian Academies of Medicine of which he was the Perpetual Secretary until 2022. He was nominated Baron in 2017, by King Philippe for his achievements.

Patrick STRAGIER, (PhD)

NOSHAQ SPIN-OFFS REPRESENTATIVE

Patrick Stragier is a biochemist with 30+ years of experience in the biopharmaceutical industry in the areas of vaccine, recombinant protein and cell and gene therapy, both in Europe and North America.
He worked for several biopharmaceutical companies (Solvay, DSM-Biologics and Genzyme) as well as for cell and gene therapy companies (Promethera, Glycostem, Lonza and Catalent), where he occupied various technical and senior managerial positions. He is also a co-founder of Masthercell, a Belgian based cell therapy CDMO, and joined Noshaq as investment manager in 2021.

Stéphane SILVENTE, MBA

CO-FOUNDER

Over 30 years of experience in management positions in the biotech and foodtech industries. Stéphane previously developed breakthrough technology in the food industry, generating several patents sold to Nestlé. In 2002, Stéphane founded and led as Chairman and CEO Affichem SA, a French biotech company which develops drug candidates in oncology, neurology and dermo-cosmetics. In 2018, Stéphane was appointed CEO of Dendrogenix SA. Stéphane is graduated from the EDC Paris Business School, obtained a DESS from the University of Valenciennes and MBA from the Toulouse Business School.

Stéphane SILVENTE, MBA

CHIEF EXECUTIVE OFFICER

Over 30 years of experience in management positions in the biotech and foodtech industries. Stéphane previously developed breakthrough technology in the food industry, generating several patents sold to Nestlé. In 2002, Stéphane founded and led as Chairman and CEO Affichem SA, a French biotech company which develops drug candidates in oncology, neurology and dermo-cosmetics. In 2018, Stéphane was appointed CEO of Dendrogenix SA. Stéphane is graduated from the EDC Paris Business School, obtained a DESS from the University of Valenciennes and MBA from the Toulouse Business School.

Philippe LEFEBVRE (MD, PhD)

CO-FOUNDER

Graduated Doctor of Medicine from the University of Liège in 1987, Philippe Lefebvre had already acquired experience in the field of research during his studies since 1981 under the direction of Professor Gustave Moonen. He earned the title of Doctor of Biomedical Science in 1991. In 1997, he was appointed clinical professor at the University of Liège. In 2002, he was appointed Professor of ENT at the University of Liège and Head of the ENT Department, a post he still holds today. Philippe Lefebvre has gained a worldwide reputation in the field of the neurobiology of the inner ear, in the pathophysiology of deafness and in the treatment of hearing loss.

Emile LORIA, MD

CHAIRMAN OF THE BOARD

Emile was a researcher in the cancer institute in Villejuif and then in the Cancer and Immunogenetics Institute (INSERM-CNRS) founded by Professor Georges Mathe. In 1986, he founded MS Medical Synergy, a company that specializes in drug management, after which he joined Biovector Therapeutics and became chairman and CEO. Emile Loria is chairman and co-founder of OSE Pharma. He has more than 25 years of experience in the pharmaceutical and biotechnology sectors, occupying key positions, in particular within Ciba-Geigy and Sanofi Pharma.

Gérard TOBELEM, MD

CO-FOUNDER

Gérard Tobelem is a former haematology professor at Paris 7 University and former Head of the department of blood disorders at the Lariboisière hospital in Paris, as well as past Executive Chairman of the French Blood Establishment. Gérard Tobelem’s research work was recognized when, in 2006, he was awarded the first Diderot Innovation prize. He has practiced strategic functions within the French Ministry of Higher Education and Research and has also advised different international pharmaceutical companies in their R&D strategies. Gérard Tobelem currently serves as non-executive Chairman of the Board of Directors of Theradiag.

Frédéric THIVET

CHIEF FINANCIAL OFFICER

As an experienced lawyer and senior manager Frederic developed skills in legal, finance, administration and HR.

Philippe LEFEBVRE, MD, PhD

CHIEF SCIENTIFIC OFFICER

Graduated Doctor of Medicine from the University of Liège in 1987, Philippe Lefebvre had already acquired experience in the field of research during his studies since 1981 under the direction of Professor Gustave Moonen. He earned the title of Doctor of Biomedical Science in 1991. In 1997, he was appointed clinical professor at the University of Liège. In 2002, he was appointed Professor of ENT at the University of Liège and Head of the ENT Department, a post he still holds today. Philippe Lefebvre has gained a worldwide reputation in the field of the neurobiology of the inner ear, in the pathophysiology of deafness and in the treatment of hearing loss.

Pierre ATTALI, MD

Pierre ATTALI, MD

CHIEF MEDICAL OFFICER

Dr. Pierre ATTALI has over 30 years’ experience in global R&D in the life sciences industry.

Nicolas CARON, PhD

HEAD OF PRECLINICAL DEVELOPMENT

Nicolas started his career in the biotech industry with Affichem where he managed several preclinical projects.

Arnaud RIVES, PhD

HEAD OF CHEMISTRY

Arnaud has 10 years’ experience in multi-step synthesis and implementation of optimization processes.

Quentin MARLIER, PhD

HEAD OF BIOLOGY

Quentin completed his thesis at the GIGA on cell cycle dysregulation in central nervous system pathologies.

Gary SCHONBERG

CHIEF BUSINESS DEVELOPMENT OFFICER

Gary was involved or led many licensing, fundraising, equity capital markets and M&A deals in the life sciences industry.

Déclarations de confidentialité

Déclaration de confidentialité à l’attention des Participants aux Essais cliniques : télécharger le document .PDF